Franklin FTSE Germany ETFの空売り状況は、投資家がFranklin FTSE Germany ETFの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Franklin FTSE Germany ETF (ARCA:FLGR), 空売り情報

Franklin FTSE Germany ETF

Financial Services

Industrials

Technology

Consumer Cyclical

Basic Materials

Healthcare

Communication Services

Utilities

Consumer Defensive

Real Estate

Under normal market conditions, the Fund invests at least 80 percent of its assets in the component securities of the FTSE Germany Capped Index and in depositary receipts representing such securities. The FTSE Germany Capped Index is a free float-adjusted market capitalization weighted index maintained and calculated by FTSE Russell with a capping methodology applied quarterly to issuer weights so that no single issuer of a component exceeds 25 percent of the FTSE Germany Capped Index weight, and all issuers with weights above 5 percent do not cumulatively exceed 50 percent of the FTSE Germany Capped Indexs weight. The FTSE Germany Capped Index is based on the FTSE Germany Index and is designed to measure the performance of German large- and mid-capitalization stocks. FTSE Russell determines eligible securities for the FTSE Germany Capped Index based on measures such as the companys place of incorporation, listing country, investor protection regulations present in the country of incorporation, tax domicile, location of headquarters/factors of production and currency of denomination.

Sap Se Common Stock Eur

Siemens AG

AHP:APH

Deutsche Telekom AG Na

Infineon Technolog

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.stoketherapeutics.com%2F&amp;esheet=54173319&amp;newsitemid=20250106021231&amp;lan=en-US&amp;anchor=Stoke+Therapeutics%2C+Inc.&amp;index=1&amp;md5=454f1331ad469e0bb2ff820d8c29374c">Stoke Therapeutics, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STOK#NASDAQ">STOK</a>), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today announced that its management team will host a webcast and conference call for investors and analysts to discuss successful alignment with global regulatory agencies related to a Phase 3 study of zorevunersen as potentially the first disease-modifying medicine for the treatment of Dravet syndrome.
The webcast will be conducted Tuesday, January 7, 2025 at 8:00am Eastern Time and can be accessed from the Investors &amp; News section of Stoke's website at <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Finvestor.stoketherapeutics.com%2F&amp;esheet=54173319&amp;newsitemid=20250106021231&amp;lan=en-US&amp;anchor=https%3A%2F%2Finvestor.stoketherapeutics.com%2F&amp;index=2&amp;md5=0cb1b30b6a3643c6103e41277dc36c53">https://investor.stoketherapeutics.com/</a>. Research analysts who plan to join the call and participate in the Q&amp;A session may register <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fregister.vevent.com%2Fregister%2FBIfb7a43c079834c3cb6a0813f54c1059e&amp;esheet=54173319&amp;newsitemid=20250106021231&amp;lan=en-US&amp;anchor=here&amp;index=3&amp;md5=7af8fd1c74d79d04b91cc2894bac615b">here</a> to receive the dial-in details and a unique PIN. For all others, the listen-only webcast can be accessed by clicking <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fedge.media-server.com%2Fmmc%2Fp%2Fmj8c7ajk&amp;esheet=54173319&amp;newsitemid=20250106021231&amp;lan=en-US&amp;anchor=here&amp;index=4&amp;md5=8eeec19293664ff83d3ffc6172d6dc34">here</a>. A replay of the webcast will be archived and available for at least 90 days following the event.

Biotech

News

Events

General

STOK

Stoke Therapeutics To Host Webcast To Discuss Successful Global Regulatory Alignment For A Phase 3 Study Of Zorevunersen As Potentially The First Disease Modifying Medicine For Dravet Syndrome On January 7, 2025 At 8:00am Eastern Time

Management

Equus Appoints Fraser Atkinson As Chairman

– Mollie Leoni, M.D. promoted to Chief Medical Officer –
– Francis Burrows, Ph.D. promoted to Chief Scientific Officer –
– Stephen Dale, M.D., steps down as CMO and Head of R&amp;D to prioritize personal health –
SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KURA#NASDAQ">KURA</a>), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Mollie Leoni, M.D., has been promoted to Chief Medical Officer after serving as Executive Vice President of Clinical Development and clinical lead for the Company's ziftomenib program since 2020. In addition, Francis Burrows, Ph.D., has been promoted to Chief Scientific Officer after leading the Company's translational research efforts for the past nine years. Stephen Dale, M.D., has stepped down as Chief Medical Officer, effective as of January 2, 2025, to focus on recovery from personal health challenges.

KURA

Kura Oncology Announces Senior Executive Promotions; Mollie Leoni, Promoted To Chief Medical Officer; Stephen Dale Steps Down As CMO And Head Of R&D To Prioritize Personal Health

ENVX

Enovix Completes Site Acceptance Testing Of Fab2

Sheridan C. Swords, previously executive vice president, commercial liquids and natural gas gathering and processing, is assuming the newly created position of executive vice president and chief commercial officer.&nbsp;
 &nbsp;

ONEOK Names Randy N. Lentz To Newly Created Position Of Executive Vice President And COO;

<ul>
<li>Novel programs will combine validated cell-targeted LNP (ctLNP) delivery with siRNA to selectively modulate T cells in vivo</li>
<li>Programs to focus on silencing hard-to-drug targets of high therapeutic value in T cell-driven autoimmune diseases</li>
<li>Company reorganization supports evolution of ctLNP-enabled strategy and buildout of clinical capabilities ahead of first IND expected in 2H 2026</li>
</ul>
CAMBRIDGE, Mass., Jan. 06, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=027Hc0iV9b3bn31fIYu-D_K2UCwWK-kHIEeCWObZ_SYoKcLmk_FTbqmyuakhho9D_puGTMCU4fcrMVn_xRE377LIYsBdVqYhVAkwMl-lP1bnLAothOYz1lzNzcCUGCtUZ-ql2y8lzaklBO-Z3eX5LvyqZqdKorEbxHNadzB1MVHlTX8vWFpNiycqI5P_fTVwJyGqJwJziyyNlnFNSvbQ7DNZjz3EI11B6LKd-_LuIsOuQVtCVBoqV7eVloXCn-mLYI1FrHvSpQslCrcpjngxjg==">Generation Bio Co.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GBIO#NASDAQ">GBIO</a>) a biotechnology company working to change what is possible for people living with T cell-driven autoimmune diseases, announced it is leveraging its validated T cell-directed lipid nanoparticle (ctLNP) to develop siRNA therapeutics to silence disease-driving targets in T cells.

GBIO

Generation Bio To Apply ctLNP Delivery Technology To Develop siRNA Therapeutics For T Cell-Driven Autoimmune Diseases

During the interim period until the transaction closes, Ansys will continue to offer Ansys PowerArtist as part of its product line, and is committed to providing the same high-quality service its customers have come to expect.

Asset Sales

ANSS

Ansys Says Sale Of PowerArtist Is Not Material To Its Financials; Terms Of Agreement Were Not Disclosed

Ansys and Synopsys determined that the sale of PowerArtist was necessary to obtain regulatory approval for Synopsys' proposed acquisition of Ansys.

KEYS

SNPS

Ansys Enters Definitive Agreement For Sale Of Its PowerArtist Business To Keysight Technologies

<ul>
<li>Primary endpoint of overall function (ALSFRS-R) and survival, and key secondary endpoints of muscle strength and respiratory function, were not met at 24 weeks</li>
<li>Overall, DNL343 was found to be safe and well tolerated</li>
<li>Additional analyses, including neurofilament light (NfL) and other fluid biomarkers, prespecified sub-group analyses and analyses from the active treatment extension period are expected later in 2025 &nbsp;</li>
</ul>

DNLI

Denali Therapeutics Announces Topline Results For Regimen G Evaluating eIF2B Agonist DNL343 In Phase 2/3 HEALEY ALS Platform Trial; Study Did Not Meet Primary Endpoint

NNN REIT, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NNN#NYSE">NNN</a>), a real estate investment trust, today announced that Kevin B. Habicht, Executive Vice President, Chief Financial Officer, Assistant Secretary, Treasurer and the Company's principal financial officer, will retire and step down as a member of the Board of Directors effective March 31, 2025.&nbsp; Vincent H. Chao will join NNN as Executive Vice President on January 9, 2025, and assume the positions of Chief Financial Officer, Assistant Secretary and Treasurer and serve as the Company's principal financial officer effective April 1, 2025.
Mr. Habicht has served as Executive Vice President and Chief Financial Officer of the Company since December 1993, and as Treasurer of the Company since January 1998 and as a director of the Company since June 2000. Mr. Habicht served as Secretary of the Company from January 1998 to May 2003.

NNN REIT Announces Kevin B. Habicht, Executive Vice President, CFO, Assistant Secretary, Treasurer And The Co's Principal Financial Officer, Will Retire, Effective March 31, 2025. Vincent H. Chao Will Join As Executive Vice President On January 9, 2025, And Assume The Positions Of CFO, Assistant Secretary And Treasurer And Serve As The Co's Principal Financial Officer Effective April 1, 2025

Jack A. Hockema, Executive Chair of the Board of Directors and Chair of the Executive Committee of the Board, notified the Board of his decision to retire as a director of the Company, effective January 1, 2025.&nbsp;
&nbsp;

KALU

Kaiser Aluminum Names Keith A. Harvey,  Company's President, CEO And A Director, As Chairman Of The Board

Contracts

MPTI

MtronPTI Receives Over $10M Production Contract For A US Defense Program

Krystal Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRYS#NASDAQ">KRYS</a>) has outperformed the market over the past 5 years by 12.62% on an annualized basis producing an average annual return of 25.44%. Currently, Krystal Biotech has a market capitalization of $4.45 billion. 
Buying $1000 In KRYS: If an investor had bought $1000 of KRYS stock 5 years ago, it would be worth $3,017.82 today based on a price of $155.81 for KRYS at the time of writing.
<h3>Krystal Biotech's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736199008_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

KRYS

Here's How Much $1000 Invested In Krystal Biotech 5 Years Ago Would Be Worth Today

Delta Air Lines (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAL#NYSE">DAL</a>), American Airlines Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAL#NASDAQ">AAL</a>) and Southwest Airlines Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUV#NYSE">LUV</a>) shares traded higher on Monday. Here&#8217;s what <a href="https://www.benzinga.com/general/travel/25/01/42809678/delta-southwest-american-and-others-airlines-halt-over-1300-flights-on-monday-after-severe-winter-storm">you need to know</a>.
What To Know: <a href="https://www.benzinga.com/general/travel/24/12/42705878/airline-stocks-outperform-tech-in-2024-holiday-travel-expected-to-see-records-this-year">Airlines</a> and other travel-related stocks moved higher on Monday after Transportation Security Administration (TSA) traveler screening data showed record travel figures for the end of 2024.
Near the end of last week, TSA <a href="https://x.com/TSA/status/1875202022737412371">posted</a> on X that it screened almost 39 million individuals from Dec. 19 through Jan. 2, marking its &#8220;busiest end of year travel period ever.&#8221; For all of 2024, TSA said officers screened a record 904 million people at airport checkpoints across the nation.
The government agency <a href="https://www.tsa.gov/travel/passenger-volumes/2024">reported</a> that 2,172,907 travelers were screened on New Year&#8217;s Eve, 2,039,342 were screened on Christmas and 1,551,896 were screened on Thanksgiving.
The increase in TSA screenings indicates strong demand for air travel during the holiday season, which may boost ticket sales and revenue for airlines. Additionally, the high number of passengers highlights the resilience of the travel industry, suggesting continued post-pandemic growth.
Investors won&#8217;t have to wait long to get holiday travel data from the airlines. Notably, Delta is expected to release 2024 fourth-quarter and fiscal-year earnings at the end of the week. Analysts expect quarterly earnings per share of $1.76 and revenue of $14.19 billion, according to estimates from <a href="http://pro.benzinga.com">Benzinga Pro</a>. Several other airlines are scheduled to report earnings in the coming weeks. 
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/25/01/42828238/gemini-resolves-cftc-lawsuit-with-5m-settlement-over-bitcoin-futures-misstatements">Gemini Resolves CFTC Lawsuit With $5M Settlement Over Bitcoin Futures Misstatements</a>
DAL, AAL, LUV Price Action: Delta shares shares closed Monday up 1.75% at $60.03, American shares closed the day up 3.24% at $17.52 and Southwest shares closed up 0.62% at $33.82, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Image via Shutterstock

Travel

Movers

What's Going On With Delta, American And Southwest Airlines Shares Monday?

APA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APA#NASDAQ">APA</a>) today announced key updates to its executive leadership and corporate officers.
Clay Bretches, executive vice president, Operations, has announced plans to retire July 1, 2025. As part of its commitment to maintaining excellence in operations, the company has launched an internal and external search for a new leader to drive continued innovation and operational efficiency. Bretches will remain with the organization and help ensure a smooth transition to a new leader, anticipated in the first half of 2025.

APA Corporation Announces Clay Bretches, Executive Vice President, Operations, Has Announced Plans To Retire July 1, 2025

New financing arrangement reduces Company's cost of capital by approximately 40%
Further enhances financial flexibility, cash generation and ability to support growth strategy
CHICAGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- FreightCar America, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAIL#NASDAQ">RAIL</a>) ("FreightCar America" or the "Company"), a diversified manufacturer and supplier of railroad freight cars, railcar parts and components, today announced it has completed a new term loan facility. The proceeds from the term loan will be used to redeem all outstanding shares of Series C Preferred Stock, as well as settle all related accrued dividends.
Highlights:
<ul>
<li>The Company closed a $115 million 4-year term loan agreement on December 31st, 2024 (the "Term Loan").</li>
<li>Proceeds from the Term Loan were used to redeem all 85,412 shares of Series C Preferred Stock that were outstanding and all accrued dividends as of December 31st, 2024.</li>
<li>The Term Loan is priced at SOFR + 600, which will reduce the Company's existing cost of capital by approximately 40%, resulting in savings of approximately $9.2 million in the first year, or approximately $0.26 per share on a fully diluted basis.</li>
</ul>

Financing

RAIL

FreightCar America Announces Agreement To Redeem All Outstanding Preferred Shares With New Term Loan; New Financing Arrangement Reduces Company's Cost Of Capital By ~40%

CX-2051 (EpCAM PROBODY ADC) has been prioritized as the Company's lead program with an initial focus in advanced metastatic CRC.
Early-stage research and platform capabilities to be concentrated on existing and potential future partnerships during 2025.
&nbsp;

CTMX

CytomX Therapeutics Expects Revised Focus And Associated Cost And Headcount Reductions  To Extend Cash Runway Into Q2 Of 2026

Macquarie analyst Tim Nollen maintains Comcast (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCSA#NASDAQ">CMCSA</a>) with a Neutral and maintains $42 price target.

Price Target

Analyst Ratings

CMCSA

Macquarie Maintains Neutral on Comcast, Maintains $42 Price Target

Omega Healthcare Investors Appoints Matthew Gourmand As President; COO Dan Booth Resigns

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Furl.avanan.click%2Fv2%2F___http%3A%2Fwww.heliostechnologies.com___.YXAzOmtlaWFkdmlzb3JzOmE6bzphNTEwZmNmMjRiNzQwOWQxNjcwNGFjOTcyMjUxOGQ5Njo2OmZiN2Y6YjhmNjVmYzJmYjE0NzI0ZjcxY2VhYzM4MTI0MmFjOTIyZGQ1MjcxN2Q5ZTFlOTA5NGI0YWRjNzhhNWNlYWQzYjpwOlQ6Rg&amp;esheet=54173872&amp;newsitemid=20250106056303&amp;lan=en-US&amp;anchor=Helios+Technologies&amp;index=1&amp;md5=d9b68e235490322f6e275f35549e2206">Helios Technologies</a>, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLIO#NYSE">HLIO</a>) ("Helios" or the "Company"), a global leader in highly engineered motion control and electronic controls technology, today announced that its Board of Directors has promoted Sean P. Bagan to President and Chief Executive Officer, effective immediately. Mr. Bagan has also been nominated to the Company's Board of Directors and will be eligible for election at the June 2025 Annual Meeting. The Board, through an external search firm, conducted a thorough search process consisting of internal and external candidates. Mr. Bagan has been serving as the Interim President, Chief Executive Officer and Chief Financial Officer <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.heliostechnologies.com%2Fnews%2Fpress-releases%2Fdetail%2F292%2Fhelios-technologies-announces-leadership-team-update&amp;esheet=54173872&amp;newsitemid=20250106056303&amp;lan=en-US&amp;anchor=since+July+8%2C+2024&amp;index=2&amp;md5=273ae25b7dca71647c7241ef6038fe8c">since July 8, 2024</a>. He will continue as Chief Financial Officer as Helios will now initiate a search to backfill Mr. Bagan's previous role. In addition, Philippe Lemaitre will resume his role as Non-Executive Chairman.

HLIO

Helios Technologies Appoints Sean P. Bagan As President And CEO, Effective Immediately

4 Things On Our Radar

Germany's service sector activity ticks higher in December

European indexes start the week in green, PMI readings in focus

European indexes gain with PMI readings in focus, Germany's inflation reading due

Germany inflation expected to rise to 2.6% in December

Germany inflation rises for the third month to 2.6%

Germany's inflation expected to rise to 2.2% in November

German Inflation Ends The Year Too High

European indexes on the rise, Germany's inflation expected to uptick

European indexes on track to close higher, Germany's inflation expected to uptick

Comments

Franklin FTSE Germany ETF

空売り

Franklin FTSE Germany ETF (ARCA:FLGR), 空売り情報

ニュース

パートナーシップ

ベンジンガ・グローバル